BiotechTube
AllerGenis

AllerGenis

Philadelphia, United States· Est.
allergenis.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

AllerGenis is a private, pre-revenue diagnostics company pioneering a data-driven approach to food allergy testing. By integrating machine learning with detailed immunology profiling, the company aims to move beyond traditional IgE tests to offer predictive diagnostics that can distinguish between true clinical allergies and mere sensitization. This precision has the potential to reduce unnecessary food eliminations, improve patient quality of life, and support the development of targeted therapies. The company's success hinges on clinical validation, adoption by allergists, and navigating a competitive diagnostic landscape.

Allergy & Immunology

Technology Platform

Integrated diagnostic platform combining high-resolution immunology profiling (e.g., epitope-specific IgE, IgG, basophil activation) with proprietary machine learning algorithms to predict clinical food allergy reactivity and severity.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The rising prevalence of food allergies and the limitations of current IgE tests create a large, underserved market for precision diagnostics.
The growth of food allergy therapies (OIT, biologics) increases the need for companion diagnostics to stratify patients.
The platform's extensibility allows for expansion into multiple allergen-specific tests.

Risk Factors

Key risks include the failure of the ML models to validate in large, diverse clinical cohorts, challenges in obtaining FDA clearance and insurance reimbursement, and slow adoption by clinicians accustomed to traditional tests.
Competition from other diagnostic innovators also poses a threat.

Competitive Landscape

AllerGenis competes with large diagnostic companies (Thermo Fisher/Phadia, Quest, LabCorp) offering standard IgE tests, as well as other startups exploring component-resolved diagnostics (CRD) and epitope mapping. Its differentiation lies in the integration of multi-parameter immune data with proprietary AI/ML for predictive clinical scoring.

More companies in Diagnostics & Precision Medicine →More companies in United States →